STRATA Skin Sciences, Inc.

Equities

SSKN

US86272A2069

Advanced Medical Equipment & Technology

Delayed Nasdaq 12:38:30 2024-04-23 pm EDT 5-day change 1st Jan Change
0.54 USD +1.89% Intraday chart for STRATA Skin Sciences, Inc. +8.54% -1.84%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
STRATA Skin Sciences, Inc. Announces Renewal of Exclusive Distribution Agreements in China and Japan CI
Top Premarket Decliners MT
Transcript : STRATA Skin Sciences, Inc., Q4 2023 Earnings Call, Mar 27, 2024
STRATA Skin Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Strata Skin Sciences Expands Distribution Deal With Kosmo Meditech MT
STRATA Skin Sciences, Inc. Announces Expansion of Distribution Agreement with Kosmo Meditech CI
Strata Skin Sciences, Inc. Promotes Shmuel Gov to the Position of Chief Operating Officer CI
Transcript : STRATA Skin Sciences, Inc., Q3 2023 Earnings Call, Nov 14, 2023
Earnings Flash (SSKN) STRATA SKIN SCIENCES Reports Q3 Revenue $8.9M, vs. Street Est of $8.72M MT
STRATA Skin Sciences, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023 CI
Strata Skin Sciences Says CEO Bob Moccia Stepping Down, Dolev Rafaeli Named CEO; Shares Drop MT
STRATA Skin Sciences, Inc. Announces CEO Changes CI
STRATA Skin Sciences, Inc. Announces Management Change CI
Transcript : STRATA Skin Sciences, Inc. - Special Call
Transcript : STRATA Skin Sciences, Inc., Q2 2023 Earnings Call, Aug 09, 2023
Earnings Flash (SSKN) STRATA SKIN SCIENCES Reports Q2 Revenue $8.3M, vs. Street Est of $8.8M MT
STRATA Skin Sciences, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2023 CI
Strata Skin Sciences Obtains Additional $12 Million Financing From MidCap Financial MT
Strata Skin Sciences Names Uri Geiger as Chairman MT
STRATA Skin Sciences, Inc. Announces Board Changes CI
Strata Skin Sciences Treats First Six Patients in TheraClearX Study MT
STRATA Skin Sciences, Inc. Announces First Patients Treated in TheraClear®X Clinical Study for Acne CI
STRATA Skin Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Transcript : STRATA Skin Sciences, Inc., Q1 2023 Earnings Call, May 15, 2023
Earnings Flash (SSKN) STRATA SKIN SCIENCES Posts Q1 Revenue $7.6M, vs. Street Est of $7.5M MT
Chart STRATA Skin Sciences, Inc.
More charts
STRATA Skin Sciences, Inc. is a medical technology company in dermatology. The Company is engaged in developing, commercializing and marketing products for the treatment of dermatologic conditions. The Company operates through two segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. The Company’s products include the XTRAC and Pharos excimer lasers and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its products also include the TheraClear Acne Therapy System utilized in the treatment of mild to moderate inflammatory, comedonal and pustular acne. The XTRAC and Pharos excimer laser technology emits highly concentrated ultraviolet (UV) light targeted primarily towards autoimmune dermatological skin disorders, such as psoriasis, vitiligo, atopic dermatitis, and eczema, among others. VTRAC is a UV light lamp system that works in much the same way as the XTRAC.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.53 USD
Average target price
2.3 USD
Spread / Average Target
+333.96%
Consensus
  1. Stock Market
  2. Equities
  3. SSKN Stock
  4. News STRATA Skin Sciences, Inc.
  5. Strata Skin Sciences Forecasts Higher-Than-Expected Sales for Q4